(R)-2-(trimethylsilyl)ethyl 2-(3,4-dichlorophenyl)-2-methyl-4-oxobutanoate | 1563182-56-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (R)-2-(trimethylsilyl)ethyl 2-(3,4-dichlorophenyl)-2-methyl-4-oxobutanoate
• CAS: 1563182-56-8
• 化学式: C₁₆H₂₂Cl₂O₃Si
• 分子量: 361.34
• InChiKey: HSPVXQHPJOGTRZ-MRXNPFEDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.72
• 重原子数：
  22.0
• 可旋转键数：
  7.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  43.37
• 氢给体数：
  0.0
• 氢受体数：
  3.0

反应信息

• 作为反应物：
  描述：

  (R)-2-(trimethylsilyl)ethyl 2-(3,4-dichlorophenyl)-2-methyl-4-oxobutanoate 在 四丁基氟化铵 作用下， 以 四氢呋喃 、 1,2-二氯乙烷 为溶剂， 反应 40.0h， 生成 2-((S)-2-((R)-2-(3,4-dichlorophenyl)-4-(6-fluoro-1-methyl-2-oxo-1,2-dihydrospiro[benzo[d][1,3]oxazine-4,4'-piperidine]-1'-yl)-2-methyl butanamido)-3-phenylpropanamido)ethyl carbamic acid benzyl ester
  参考文献：
  名称：

  Design, Synthesis, and Optimization of Balanced Dual NK₁/NK₃Receptor Antagonists

  摘要：

  In connection with a program directed at potent and balanced dual NK1/NK3 receptor ligands, a focused exploration of an original class of peptidomimetic derivatives was performed. The rational design and molecular hybridization of a novel phenylalanine core series was achieved to maximize the in vitro affinity and antagonism at both human NK1 and NK3 receptors. This study led to the identification of a new potent dual NK1/NK3 antagonist with pK(i) values of 8.6 and 8.1, respectively.

  DOI：

  10.1021/ml400528y
• 作为产物：
  描述：

  2-(3,4-dichlorophenyl)-2-methylpent-4-enoic acid 在 吡啶 、 盐酸 、 4-二甲氨基吡啶 、 sodium periodate 、 四氧化锇 、 N-甲基吗啉氧化物 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 四氢呋喃 、 水 、 乙酸乙酯 为溶剂， 反应 36.0h， 生成 (R)-2-(trimethylsilyl)ethyl 2-(3,4-dichlorophenyl)-2-methyl-4-oxobutanoate
  参考文献：
  名称：

  Design, Synthesis, and Optimization of Balanced Dual NK₁/NK₃Receptor Antagonists

  摘要：

  In connection with a program directed at potent and balanced dual NK1/NK3 receptor ligands, a focused exploration of an original class of peptidomimetic derivatives was performed. The rational design and molecular hybridization of a novel phenylalanine core series was achieved to maximize the in vitro affinity and antagonism at both human NK1 and NK3 receptors. This study led to the identification of a new potent dual NK1/NK3 antagonist with pK(i) values of 8.6 and 8.1, respectively.

  DOI：

  10.1021/ml400528y